Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	antigen binding	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-30-3 IGHV3-43D IGHV3-74 IGHV3-66	1.37e-19	190	71	17	GO:0003823
GeneOntologyMolecularFunction	cargo receptor ligand activity	CBLIF TCN1	7.44e-05	4	71	2	GO:0140355
GeneOntologyMolecularFunction	structural constituent of muscle	MYH8 KRT19 NEB	4.80e-04	43	71	3	GO:0008307
GeneOntologyMolecularFunction	cobalamin binding	CBLIF TCN1	5.51e-04	10	71	2	GO:0031419
GeneOntologyMolecularFunction	intramembrane lipid transporter activity	VMP1 ABCA12 ANO10	7.94e-04	51	71	3	GO:0140303
GeneOntologyBiologicalProcess	immunoglobulin mediated immune response	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-30-3 IGHV3-43D IGHV3-74 IGHV3-66	1.81e-18	235	69	17	GO:0016064
GeneOntologyBiologicalProcess	B cell mediated immunity	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-30-3 IGHV3-43D IGHV3-74 IGHV3-66	3.43e-18	244	69	17	GO:0019724
GeneOntologyBiologicalProcess	lymphocyte mediated immunity	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-30-3 IGHV3-43D IGHV3-74 IGHV3-66	8.65e-14	449	69	17	GO:0002449
GeneOntologyBiologicalProcess	adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-30-3 IGHV3-43D IGHV3-74 IGHV3-66	1.37e-13	462	69	17	GO:0002460
GeneOntologyBiologicalProcess	leukocyte mediated immunity	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-30-3 ACE IGHV3-43D IGHV3-74 IGHV3-66	3.77e-13	576	69	18	GO:0002443
GeneOntologyBiologicalProcess	immune effector process	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-30-3 ACE IGHV3-43D IGHV3-74 IGHV3-66	2.77e-10	859	69	18	GO:0002252
GeneOntologyBiologicalProcess	adaptive immune response	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-30-3 IGHV3-43D IGHV3-74 IGHV3-66	1.56e-09	838	69	17	GO:0002250
GeneOntologyBiologicalProcess	musculoskeletal movement	CACNA1A MYH8 GAA CHUK	8.42e-05	69	69	4	GO:0050881
GeneOntologyBiologicalProcess	multicellular organismal movement	CACNA1A MYH8 GAA CHUK	1.05e-04	73	69	4	GO:0050879
GeneOntologyBiologicalProcess	cobalt ion transport	CBLIF TCN1	3.05e-04	8	69	2	GO:0006824
GeneOntologyBiologicalProcess	epithelium development	GLMN IGF1R KRT15 DLC1 KRT16 CLASP1 KRT19 ABCA12 NUP210L SLITRK6 CUX1 CHUK PML PCNT	3.07e-04	1469	69	14	GO:0060429
GeneOntologyCellularComponent	immunoglobulin complex	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-30-3 IGHV3-43D IGHV3-74 IGHV3-66	6.15e-21	166	71	17	GO:0019814
GeneOntologyCellularComponent	ciliary rootlet	RPGRIP1 KLC2 KLC1	2.04e-05	16	71	3	GO:0035253
GeneOntologyCellularComponent	supramolecular fiber	MYH8 KRT15 DLC1 KRT16 CLASP1 KRT19 KLC2 NEB DNAH5 KLC1 PCNT COL1A1	5.71e-04	1179	71	12	GO:0099512
GeneOntologyCellularComponent	supramolecular polymer	MYH8 KRT15 DLC1 KRT16 CLASP1 KRT19 KLC2 NEB DNAH5 KLC1 PCNT COL1A1	6.06e-04	1187	71	12	GO:0099081
MousePheno	translucent skin	IGF1R ABCA12 CHUK	1.38e-05	15	45	3	MP:0001201
Domain	DUF4430	CBLIF TCN1	2.19e-05	3	51	2	IPR027954
Domain	COBALAMIN_BINDING	CBLIF TCN1	2.19e-05	3	51	2	PS00468
Domain	DUF4430	CBLIF TCN1	2.19e-05	3	51	2	PF14478
Domain	Cobalamin_bind	CBLIF TCN1	2.19e-05	3	51	2	PF01122
Domain	Cbl-bd_transpt_euk	CBLIF TCN1	2.19e-05	3	51	2	IPR002157
Domain	Kinesin_light_repeat	KLC2 KLC1	2.19e-05	3	51	2	IPR015792
Domain	KINESIN_LIGHT	KLC2 KLC1	2.19e-05	3	51	2	PS01160
Domain	Kinesin_light	KLC2 KLC1	4.37e-05	4	51	2	IPR002151
Domain	Rab5-bind	KLC2 KLC1	1.09e-04	6	51	2	PF09311
Domain	Rabaptin_Rab5-bd_dom	KLC2 KLC1	1.09e-04	6	51	2	IPR015390
Domain	TPR_10	KLC2 KLC1	1.09e-04	6	51	2	PF13374
Domain	LRR	PPP1R37 SLITRK6 NRROS NXF1 LRRC23	2.16e-04	201	51	5	PS51450
Domain	Keratin_I	KRT15 KRT16 KRT19	2.35e-04	44	51	3	IPR002957
Domain	L_dom-like	IGF1R PPP1R37 SLITRK6 NRROS NXF1 LRRC23	2.59e-04	328	51	6	IPR032675
Domain	LRR_6	PPP1R37 NRROS LRRC23	4.55e-04	55	51	3	PF13516
Domain	Intermediate_filament_CS	KRT15 KRT16 KRT19	6.79e-04	63	51	3	IPR018039
Domain	Leu-rich_rpt	PPP1R37 SLITRK6 NRROS NXF1 LRRC23	8.44e-04	271	51	5	IPR001611
Domain	Filament	KRT15 KRT16 KRT19	9.62e-04	71	51	3	SM01391
Domain	Prefoldin	KRT15 KRT19 KLC2	1.00e-03	72	51	3	IPR009053
Domain	IF	KRT15 KRT16 KRT19	1.00e-03	72	51	3	PS00226
Domain	Filament	KRT15 KRT16 KRT19	1.04e-03	73	51	3	PF00038
Domain	IF	KRT15 KRT16 KRT19	1.17e-03	76	51	3	IPR001664
Domain	Pentatricopeptide_repeat	KLC2 KLC1	1.78e-03	23	51	2	IPR002885
Domain	-	PPP1R37 SLITRK6 NRROS NXF1 LRRC23	1.79e-03	321	51	5	3.80.10.10
Domain	LRR_1	SLITRK6 NRROS NXF1 LRRC23	2.99e-03	219	51	4	PF00560
Pathway	REACTOME_CD22_MEDIATED_BCR_REGULATION	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	8.45e-24	35	53	13	MM17219
Pathway	REACTOME_ANTIGEN_ACTIVATES_B_CELL_RECEPTOR_BCR_LEADING_TO_GENERATION_OF_SECOND_MESSENGERS	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66 ITPR2	3.74e-23	53	53	14	MM15716
Pathway	REACTOME_CLASSICAL_ANTIBODY_MEDIATED_COMPLEMENT_ACTIVATION	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	4.60e-23	39	53	13	MM17212
Pathway	REACTOME_ROLE_OF_LAT2_NTAL_LAB_ON_CALCIUM_MOBILIZATION	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	4.07e-22	45	53	13	MM14912
Pathway	REACTOME_FCGR_ACTIVATION	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	1.07e-21	48	53	13	MM17214
Pathway	REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	6.03e-21	54	53	13	MM14655
Pathway	REACTOME_ROLE_OF_PHOSPHOLIPIDS_IN_PHAGOCYTOSIS	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	1.02e-20	56	53	13	MM14815
Pathway	REACTOME_FCERI_MEDIATED_CA_2_MOBILIZATION	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	1.70e-20	58	53	13	MM14914
Pathway	REACTOME_BINDING_AND_UPTAKE_OF_LIGANDS_BY_SCAVENGER_RECEPTORS	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	2.77e-20	60	53	13	MM14872
Pathway	REACTOME_FCERI_MEDIATED_MAPK_ACTIVATION	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	2.77e-20	60	53	13	MM14913
Pathway	REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 CHUK IGHV3-66 ITPR2	6.79e-19	131	53	15	MM15717
Pathway	REACTOME_FCERI_MEDIATED_NF_KB_ACTIVATION	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 CHUK IGHV3-66	1.65e-18	107	53	14	MM14915
Pathway	REACTOME_COMPLEMENT_CASCADE	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	3.15e-18	84	53	13	MM14653
Pathway	REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66 COL1A1	4.80e-17	135	53	14	MM14781
Pathway	REACTOME_FCGAMMA_RECEPTOR_FCGR_DEPENDENT_PHAGOCYTOSIS	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	2.01e-16	114	53	13	MM14814
Pathway	REACTOME_FC_EPSILON_RECEPTOR_FCERI_SIGNALING	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 CHUK IGHV3-66	2.17e-16	150	53	14	MM14889
Pathway	REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66 COL1A1	4.54e-16	158	53	14	MM14812
Pathway	REACTOME_ADAPTIVE_IMMUNE_SYSTEM	IGHV3-53 IGHV3-48 GLMN IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 KLHL13 KLC2 KLC1 IGHV3-74 CHUK IGHV3-66 COL1A1 ITPR2	4.51e-13	719	53	20	MM14540
Pathway	REACTOME_HEMOSTASIS	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 KLC2 KLC1 IGHV3-74 IGHV3-66 COL1A1 ITPR2	1.40e-11	571	53	17	MM14472
Pathway	REACTOME_ROLE_OF_PHOSPHOLIPIDS_IN_PHAGOCYTOSIS	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 ITPR2	1.75e-11	82	53	9	M27110
Pathway	REACTOME_ANTIGEN_ACTIVATES_B_CELL_RECEPTOR_BCR_LEADING_TO_GENERATION_OF_SECOND_MESSENGERS	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 ITPR2	2.71e-11	86	53	9	M601
Pathway	REACTOME_FCERI_MEDIATED_CA_2_MOBILIZATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 ITPR2	2.71e-11	86	53	9	M27206
Pathway	REACTOME_CD22_MEDIATED_BCR_REGULATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7	5.81e-11	61	53	8	M27581
Pathway	REACTOME_FCGR3A_MEDIATED_IL10_SYNTHESIS	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 ITPR2	6.76e-11	95	53	9	M29842
Pathway	REACTOME_BINDING_AND_UPTAKE_OF_LIGANDS_BY_SCAVENGER_RECEPTORS	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 COL1A1	8.98e-11	98	53	9	M27152
Pathway	REACTOME_FCGR_ACTIVATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7	1.61e-10	69	53	8	M27108
Pathway	REACTOME_SCAVENGING_OF_HEME_FROM_PLASMA	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7	1.61e-10	69	53	8	M27150
Pathway	REACTOME_CREATION_OF_C4_AND_C2_ACTIVATORS	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7	2.04e-10	71	53	8	M1078
Pathway	REACTOME_ROLE_OF_LAT2_NTAL_LAB_ON_CALCIUM_MOBILIZATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7	2.04e-10	71	53	8	M27203
Pathway	REACTOME_SIGNALING_BY_THE_B_CELL_RECEPTOR_BCR	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 CHUK ITPR2	4.92e-10	166	53	10	M608
Pathway	REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7	5.42e-10	80	53	8	M6121
Pathway	REACTOME_FCERI_MEDIATED_MAPK_ACTIVATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7	1.07e-09	87	53	8	M27205
Pathway	REACTOME_FC_EPSILON_RECEPTOR_FCERI_SIGNALING	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 CHUK ITPR2	1.50e-09	186	53	10	M27175
Pathway	REACTOME_ANTI_INFLAMMATORY_RESPONSE_FAVOURING_LEISHMANIA_PARASITE_INFECTION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 ITPR2	1.50e-09	134	53	9	M29840
Pathway	REACTOME_FCERI_MEDIATED_NF_KB_ACTIVATION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 CHUK	1.72e-09	136	53	9	M27207
Pathway	REACTOME_FCGAMMA_RECEPTOR_FCGR_DEPENDENT_PHAGOCYTOSIS	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 ITPR2	2.68e-09	143	53	9	M27107
Pathway	REACTOME_VESICLE_MEDIATED_TRANSPORT	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 KLC2 KLC1 IGHV3-74 IGHV3-66	8.49e-09	645	53	15	MM15232
Pathway	REACTOME_COMPLEMENT_CASCADE	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7	1.00e-08	115	53	8	M19752
Pathway	REACTOME_PARASITE_INFECTION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7	1.07e-08	116	53	8	M29843
Pathway	REACTOME_IMMUNOREGULATORY_INTERACTIONS_BETWEEN_A_LYMPHOID_AND_A_NON_LYMPHOID_CELL	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 COL1A1	3.23e-08	190	53	9	M8240
Pathway	REACTOME_CELL_SURFACE_INTERACTIONS_AT_THE_VASCULAR_WALL	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 COL1A1	3.86e-08	194	53	9	M16312
Pathway	REACTOME_POTENTIAL_THERAPEUTICS_FOR_SARS	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7	9.88e-08	154	53	8	M39007
Pathway	REACTOME_LEISHMANIA_INFECTION	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 ITPR2	1.10e-07	219	53	9	M29836
Pathway	REACTOME_ADAPTIVE_IMMUNE_SYSTEM	IGHV3-53 IGHV3-48 GLMN IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 KLHL13 KLC2 KLC1 CHUK COL1A1 ITPR2	2.30e-07	828	53	15	M1058
Pathway	REACTOME_INNATE_IMMUNE_SYSTEM	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 GAA IGHV3-74 CHUK IGHV3-66	2.37e-06	995	53	15	MM14661
Pathway	REACTOME_VIRAL_INFECTION_PATHWAYS	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGF1R IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 ELK1 ANO10 MED23 CHUK PML	3.33e-06	888	53	14	M48034
Pathway	REACTOME_HEMOSTASIS	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 KLC2 KLC1 COL1A1 ITPR2	6.12e-06	679	53	12	M8395
Pathway	REACTOME_INFECTIOUS_DISEASE	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGF1R IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 ELK1 ANO10 MED23 CHUK PML ITPR2	6.59e-06	1081	53	15	M27548
Pathway	REACTOME_SARS_COV_INFECTIONS	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 ANO10 CHUK	8.45e-06	471	53	10	M39009
Pathway	REACTOME_VESICLE_MEDIATED_TRANSPORT	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7 KLC2 CUX1 KLC1 COL1A1	1.19e-05	725	53	12	M27507
Pathway	REACTOME_INNATE_IMMUNE_SYSTEM	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 TCN1 IGHV3-7 ELK1 GAA CHUK ITPR2	2.10e-04	1128	53	13	M1036
Pathway	KEGG_MEDICUS_VARIANT_MUTATION_CAUSED_ABERRANT_PSEN1_TO_ANTEROGRADE_AXONAL_TRANSPORT	KLC2 KLC1	4.91e-04	9	53	2	M47699
Pathway	REACTOME_UPTAKE_OF_DIETARY_COBALAMINS_INTO_ENTEROCYTES	CBLIF TCN1	6.12e-04	10	53	2	M45024
Pathway	REACTOME_RHO_GTPASES_ACTIVATE_KTN1	KLC2 KLC1	7.46e-04	11	53	2	M27490
Pathway	REACTOME_RHO_GTPASES_ACTIVATE_KTN1	KLC2 KLC1	7.46e-04	11	53	2	MM15218
Pathway	WP_VITAMIN_B12_DISORDERS	CBLIF TCN1	1.05e-03	13	53	2	M39778
Pathway	KEGG_MEDICUS_VARIANT_OLIGOMERIC_CONFORMATION_PRPC_TO_ANTEROGRADE_AXONAL_TRANSPORT	KLC2 KLC1	1.05e-03	13	53	2	M47763
Pathway	PID_TAP63_PATHWAY	TP53I3 CHUK PML	1.09e-03	54	53	3	M256
Pathway	KEGG_MEDICUS_REFERENCE_IGF_IGFR_PI3K_NFKB_SIGNALING_PATHWAY	IGF1R CHUK	1.23e-03	14	53	2	M47467
Pathway	KEGG_LONG_TERM_DEPRESSION	CACNA1A IGF1R ITPR2	2.30e-03	70	53	3	M8232
Pathway	BIOCARTA_IGF1_PATHWAY	IGF1R ELK1	2.78e-03	21	53	2	M2623
Pathway	BIOCARTA_RAS_PATHWAY	ELK1 CHUK	2.78e-03	21	53	2	MM1464
Pathway	BIOCARTA_IGF1_PATHWAY	IGF1R ELK1	3.05e-03	22	53	2	MM1409
Pathway	BIOCARTA_RAS_PATHWAY	ELK1 CHUK	3.05e-03	22	53	2	M17294
Pathway	REACTOME_COBALAMIN_CBL_VITAMIN_B12_TRANSPORT_AND_METABOLISM	CBLIF TCN1	3.05e-03	22	53	2	M27084
Pathway	WP_ESTROGEN_SIGNALING	ELK1 CHUK	3.34e-03	23	53	2	M39672
Pubmed	1.3 A X-ray structure of an antibody Fv fragment used for induced membrane-protein crystallization.	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	3.48e-34	15	71	13	12657787
Pubmed	Early onset of somatic mutation in immunoglobulin VH genes during the primary immune response.	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	1.63e-30	22	71	13	2499654
Pubmed	IMGT/GENE-DB: a comprehensive database for human and mouse immunoglobulin and T cell receptor genes.	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	5.54e-22	77	71	13	15608191
Pubmed	The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus.	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-66	5.47e-19	91	71	12	9841928
Pubmed	Structure and physical map of 64 variable segments in the 3'0.8-megabase region of the human immunoglobulin heavy-chain locus.	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-23 IGHV3-20 IGHV3-11 IGHV3-9 IGHV3-7	1.17e-14	39	71	8	8490662
Pubmed	Molecular analysis of spontaneous somatic mutants.	IGHV3-48 IGHV3-21 IGHV3-13 IGHV3-11 IGHV3-7	3.07e-14	5	71	5	401950
Pubmed	Heavy chain variable region contribution to the NPb family of antibodies: somatic mutation evident in a gamma 2a variable region.	IGHV3-48 IGHV3-21 IGHV3-13 IGHV3-11 IGHV3-7	2.58e-10	18	71	5	6788376
Pubmed	Control of TurboID-dependent biotinylation intensity in proximity ligation screens.	VMP1 CLASP1 NRROS PML ITPR2	1.99e-06	100	71	5	36966971
Pubmed	Crystal structures of the tetratricopeptide repeat domains of kinesin light chains: insight into cargo recognition mechanisms.	KLC2 KLC1	4.11e-06	2	71	2	22470497
Pubmed	The complete sequence of the gene encoding mouse cytokeratin 15.	KRT15 KRT19	4.11e-06	2	71	2	7510260
Pubmed	The IκB kinase inhibitor ACHP strongly attenuates TGFβ1-induced myofibroblast formation and collagen synthesis.	CHUK COL1A1	4.11e-06	2	71	2	26337045
Pubmed	Variable region sequences of five human immunoglobulin heavy chains of the VH3 subgroup: definitive identification of four heavy chain hypervariable regions.	IGHV3-23 IGHV3-7	4.11e-06	2	71	2	4522793
Pubmed	Expression of basal cell keratin 15 and keratin 19 in oral squamous neoplasms represents diverse pathophysiologies.	KRT15 KRT19	4.11e-06	2	71	2	22648550
Pubmed	Structural plasticity of the N-terminal capping helix of the TPR domain of kinesin light chain.	KLC2 KLC1	4.11e-06	2	71	2	29036226
Pubmed	Low level expression of cytokeratins 8, 18 and 19 in vascular smooth muscle cells of human umbilical cord and in cultured cells derived therefrom, with an analysis of the chromosomal locus containing the cytokeratin 19 gene.	KRT15 KRT19	4.11e-06	2	71	2	2468493
Pubmed	Genomic organization and amplification of the human keratin 15 and keratin 19 genes.	KRT15 KRT19	4.11e-06	2	71	2	10623642
Pubmed	Mediator MED23 links insulin signaling to the adipogenesis transcription cascade.	ELK1 MED23	4.11e-06	2	71	2	19460352
Pubmed	Arrangement of a cluster of three mouse type I keratin genes expressed sequentially during esophageal-type epithelial cell differentiation.	KRT15 KRT19	1.23e-05	3	71	2	7535287
Pubmed	The immunohistochemical differential diagnosis of microcystic adnexal carcinoma, desmoplastic trichoepithelioma and morpheaform basal cell carcinoma using BerEP4 and stem cell markers.	KRT15 KRT19	1.23e-05	3	71	2	23398472
Pubmed	Keratin 15, transcobalamin I and homeobox gene Hox-B13 expression in breast phyllodes tumors: novel markers in biological classification.	KRT15 TCN1	1.23e-05	3	71	2	21574054
Pubmed	Myeloid Zinc Finger 1 (MZF1) Maintains the Mesenchymal Phenotype by Down-regulating IGF1R/p38 MAPK/ERα Signaling Pathway in High-level MZF1-expressing TNBC cells.	IGF1R ELK1	1.23e-05	3	71	2	31366500
Pubmed	Biliary NIK promotes ductular reaction and liver injury and fibrosis in mice.	KRT19 CHUK	1.23e-05	3	71	2	36042192
Pubmed	The mouse homologs of human GIF, DDB1, and CFL1 genes are located on chromosome 19.	CBLIF DDB1	1.23e-05	3	71	2	9530637
Pubmed	Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS.	CUX1 COL1A1	1.23e-05	3	71	2	29592892
Pubmed	Higher-order immunoglobulin repertoire restrictions in CLL: the illustrative case of stereotyped subsets 2 and 169.	IGHV3-48 IGHV3-21	1.23e-05	3	71	2	33036024
Pubmed	Cayman ataxia protein caytaxin is transported by kinesin along neurites through binding to kinesin light chains.	KLC2 KLC1	2.46e-05	4	71	2	19861499
Pubmed	Kinesin-dependent axonal transport is mediated by the sunday driver (SYD) protein.	KLC2 KLC1	2.46e-05	4	71	2	11106729
Pubmed	PW1 gene/paternally expressed gene 3 (PW1/Peg3) identifies multiple adult stem and progenitor cell populations.	KRT15 PEG3	2.46e-05	4	71	2	21709251
Pubmed	Hippo pathway activity influences liver cell fate.	KRT19 COL1A1	2.46e-05	4	71	2	24906150
Pubmed	Nesprin 4 is an outer nuclear membrane protein that can induce kinesin-mediated cell polarization.	KLC2 KLC1	4.09e-05	5	71	2	19164528
Pubmed	Comparative analysis of cobalamin binding kinetics and ligand protection for intrinsic factor, transcobalamin, and haptocorrin.	CBLIF TCN1	4.09e-05	5	71	2	11788601
Pubmed	Sunday Driver/JIP3 binds kinesin heavy chain directly and enhances its motility.	KLC2 KLC1	4.09e-05	5	71	2	21750526
Pubmed	Calsyntenin-1 docks vesicular cargo to kinesin-1.	KLC2 KLC1	4.09e-05	5	71	2	16760430
Pubmed	Defective kinesin heavy chain behavior in mouse kinesin light chain mutants.	KLC2 KLC1	4.09e-05	5	71	2	10491391
Pubmed	An extended consensus motif enhances the specificity of substrate modification by SUMO.	ELK1 PML	6.13e-05	6	71	2	17036045
Pubmed	Cytokeratin 15 marks basal epithelia in developing ureters and is upregulated in a subset of urothelial cell carcinomas.	KRT15 KRT19	6.13e-05	6	71	2	24260555
Pubmed	Quantitative analysis of PPT1 interactome in human neuroblastoma cells.	IGHV3-30 IGHV3-23 IGHV3-13 KLC2 DDB1	7.21e-05	210	71	5	26217791
Pubmed	The novel cargo Alcadein induces vesicle association of kinesin-1 motor components and activates axonal transport.	KLC2 KLC1	8.57e-05	7	71	2	17332754
Pubmed	Stable kinesin and dynein assemblies drive the axonal transport of mammalian prion protein vesicles.	KLC2 KLC1	8.57e-05	7	71	2	21335237
Pubmed	Myosin-reactive autoantibodies in rheumatic carditis and normal fetus.	IGHV3-48 IGHV3-30	8.57e-05	7	71	2	9614934
Pubmed	CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth.	DLC1 DDB1	8.57e-05	7	71	2	24082123
Pubmed	Upregulation of neurovascular communication through filamin abrogation promotes ectopic periventricular neurogenesis.	IGF1R CUX1 PCNT	9.49e-05	43	71	3	27664421
Pubmed	Single-Cell Analysis of the Liver Epithelium Reveals Dynamic Heterogeneity and an Essential Role for YAP in Homeostasis and Regeneration.	KRT19 COL1A1	1.14e-04	8	71	2	31080134
Pubmed	Cytokeratin, vimentin and E-cadherin immunodetection in the embryonic palate in two strains of mice with different susceptibility to glucocorticoid-induced clefting.	KRT16 KRT19	1.14e-04	8	71	2	11321598
Pubmed	RUSC2 and WDR47 oppositely regulate kinesin-1-dependent distribution of ATG9A to the cell periphery.	KLC2 KLC1	1.14e-04	8	71	2	34432492
Pubmed	Skeletal muscle phenotypes initiated by ectopic MyoD in transgenic mouse heart.	MYH8 NEB	1.14e-04	8	71	2	1618148
Pubmed	An introduction of genetics in otosclerosis: a systematic review.	ACE COL1A1	1.47e-04	9	71	2	24170657
Pubmed	Type II keratins precede type I keratins during early embryonic development.	KRT15 KRT19	1.47e-04	9	71	2	16180309
Pubmed	Peg3/PW1 Is a Marker of a Subset of Vessel Associated Endothelial Progenitors.	PEG3 COL1A1	1.47e-04	9	71	2	28090691
Pubmed	Two kinesin light chain genes in mice. Identification and characterization of the encoded proteins.	KLC2 KLC1	1.47e-04	9	71	2	9624122
Pubmed	Genetics of dizziness: cerebellar and vestibular disorders.	CACNA1A ANO10	1.47e-04	9	71	2	24275721
Pubmed	Dynein and kinesin regulate stress-granule and P-body dynamics.	KLC2 KLC1	1.83e-04	10	71	2	19825938
Pubmed	Multimodal spatiotemporal transcriptomic resolution of embryonic palate osteogenesis.	LRRC23 COL1A1	1.83e-04	10	71	2	37709732
Pubmed	Spatiotemporal expression pattern of keratins in skin of AP-2alpha-deficient mice.	KRT15 KRT16	1.83e-04	10	71	2	10571739
Pubmed	SDCCAG8 regulates pericentriolar material recruitment and neuronal migration in the developing cortex.	CUX1 PCNT	1.83e-04	10	71	2	25088364
Pubmed	Content and organization of the human Ig VH locus: definition of three new VH families and linkage to the Ig CH locus.	IGHV3-13 IGHV3-66	1.83e-04	10	71	2	3396540
Pubmed	A kinesin-1 binding motif in vaccinia virus that is widespread throughout the human genome.	KLC2 KLC1	1.83e-04	10	71	2	21915095
Pubmed	Development and distribution of neuronal cilia in mouse neocortex.	CUX1 PCNT	1.83e-04	10	71	2	22020803
Pubmed	Mutations in the Cacnl1a4 calcium channel gene are associated with seizures, cerebellar degeneration, and ataxia in tottering and leaner mutant mice.	CACNA1A PEG3	1.83e-04	10	71	2	9060410
Pubmed	rec-YnH enables simultaneous many-by-many detection of direct protein-protein and protein-RNA interactions.	CLASP1 KLC2 GAA KLC1	2.09e-04	142	71	4	30217970
Pubmed	Homologs of genes expressed in Caenorhabditis elegans GABAergic neurons are also found in the developing mouse forebrain.	RPGRIP1 MYH8 CUX1	2.20e-04	57	71	3	21122108
Pubmed	Tight junction protein occludin regulates progenitor Self-Renewal and survival in developing cortex.	CUX1 PCNT	2.23e-04	11	71	2	31794381
Pubmed	Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach.	IGHV3-30 IGHV3-23 IGHV3-13 DDB1	2.52e-04	149	71	4	22664934
Pubmed	Novel embryonic neuronal migration and proliferation defects in Dcx mutant mice are exacerbated by Lis1 reduction.	CUX1 PCNT	2.68e-04	12	71	2	20181597
Pubmed	Hedgehog signaling maintains hair follicle stem cell phenotype in young and aged human skin.	KRT15 KRT19	2.68e-04	12	71	2	20050020
Pubmed	Mediator requirement for both recruitment and postrecruitment steps in transcription initiation.	ELK1 MED23	2.68e-04	12	71	2	15749018
Pubmed	The ciliary rootlet interacts with kinesin light chains and may provide a scaffold for kinesin-1 vesicular cargos.	KLC2 KLC1	2.68e-04	12	71	2	16018997
Pubmed	Coordinated transport of phosphorylated amyloid-beta precursor protein and c-Jun NH2-terminal kinase-interacting protein-1.	KLC2 KLC1	2.68e-04	12	71	2	16301330
Pubmed	The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops.	IGHV3-21 IGHV3-74	2.68e-04	12	71	2	1404388
Pubmed	New consensus nomenclature for mammalian keratins.	KRT15 KRT16 KRT19	2.97e-04	63	71	3	16831889
Pubmed	Mesenchyme-specific overexpression of nucleolar protein 66 in mice inhibits skeletal growth and bone formation.	IGF1R COL1A1	3.16e-04	13	71	2	25746793
Pubmed	Transcriptional Profiling of Insulin-like Growth Factor Signaling Components in Embryonic Lung Development and Idiopathic Pulmonary Fibrosis.	IGF1R COL1A1	3.16e-04	13	71	2	35741102
Pubmed	Usp11 controls cortical neurogenesis and neuronal migration through Sox11 stabilization.	CUX1 PML	3.16e-04	13	71	2	33579706
Pubmed	DDB1 is essential for genomic stability in developing epidermis.	KRT15 DDB1	3.16e-04	13	71	2	17301228
Pubmed	The zinc finger transcription factor PW1/PEG3 restrains murine beta cell cycling.	KRT19 PEG3	3.16e-04	13	71	2	27130279
Pubmed	Mouse placenta fetal macrophages arise from endothelial cells outside the placenta.	PCDH12 COL1A1	3.16e-04	13	71	2	36473461
Pubmed	miR-126 regulates glycogen trophoblast proliferation and DNA methylation in the murine placenta.	PEG3 PCDH12	3.16e-04	13	71	2	30771304
Pubmed	Acinar-ductal cell rearrangement drives branching morphogenesis of the murine pancreas in an IGF/PI3K-dependent manner.	IGF1R KRT19	3.68e-04	14	71	2	38237591
Pubmed	Mouse B-type lamins are required for proper organogenesis but not by embryonic stem cells.	CUX1 PCNT	3.68e-04	14	71	2	22116031
Pubmed	Developmental changes in cellular and extracellular structural macromolecules in the secondary palate and in the nasal cavity of the mouse.	KRT15 KRT19	3.68e-04	14	71	2	20572855
Pubmed	Defects in Stratum Corneum Desquamation Are the Predominant Effect of Impaired ABCA12 Function in a Novel Mouse Model of Harlequin Ichthyosis.	KRT16 ABCA12	3.68e-04	14	71	2	27551807
Pubmed	The genomic organization of type I keratin genes in mice.	KRT15 KRT19	4.24e-04	15	71	2	10087197
Pubmed	Adult interfollicular tumour-initiating cells are reprogrammed into an embryonic hair follicle progenitor-like fate during basal cell carcinoma initiation.	KRT19 CUX1	4.24e-04	15	71	2	23178882
Pubmed	Loss of CPAP in developing mouse brain and its functional implication for human primary microcephaly.	CUX1 PCNT	4.84e-04	16	71	2	32501282
Pubmed	TBX1 targets the miR-200-ZEB2 axis to induce epithelial differentiation and inhibit stem cell properties.	KRT15 KRT19	4.84e-04	16	71	2	36418889
Pubmed	Mesenchymal Deletion of Histone Demethylase NO66 in Mice Promotes Bone Formation.	IGF1R COL1A1	4.84e-04	16	71	2	25736226
Pubmed	The N6-methyladenosine-mediated lncRNA WEE2-AS1 promotes glioblastoma progression by stabilizing RPN2.	CLASP1 HMGCS1 MED23 NXF1 KLC1	5.43e-04	325	71	5	36168628
Pubmed	Defining epithelial cell dynamics and lineage relationships in the developing lacrimal gland.	KRT15 KRT19	5.48e-04	17	71	2	28576768
Pubmed	Cortical neurogenesis in the absence of centrioles.	CUX1 PCNT	5.48e-04	17	71	2	25282615
Pubmed	Splicing factor Srsf5 deletion disrupts alternative splicing and causes noncompaction of ventricular myocardium.	MYH8 NEB	5.48e-04	17	71	2	34622152
Pubmed	Kelch Domain of Gigaxonin Interacts with Intermediate Filament Proteins Affected in Giant Axonal Neuropathy.	CLASP1 ZZEF1 CUX1 PCNT	5.94e-04	187	71	4	26460568
Pubmed	Lis1-Nde1-dependent neuronal fate control determines cerebral cortical size and lamination.	CUX1 PCNT	6.16e-04	18	71	2	18469343
Pubmed	Arl13b-regulated cilia activities are essential for polarized radial glial scaffold formation.	CUX1 PCNT	6.16e-04	18	71	2	23817546
Pubmed	Patched 1 and patched 2 redundancy has a key role in regulating epidermal differentiation.	KRT15 CUX1	6.87e-04	19	71	2	24492243
Pubmed	Synapsin and synaptic vesicle protein expression during embryonic and post-natal lens fiber cell differentiation.	KLC2 KLC1	6.87e-04	19	71	2	15529118
Pubmed	Cdh1-APC Regulates Protein Synthesis and Stress Granules in Neurons through an FMRP-Dependent Mechanism.	MYH8 CLASP1 DDB1 NXF1	7.21e-04	197	71	4	32434143
Pubmed	The RepID-CRL4 ubiquitin ligase complex regulates metaphase to anaphase transition via BUB3 degradation.	DDB1 PML	7.62e-04	20	71	2	31911655
Pubmed	Layer specific and general requirements for ERK/MAPK signaling in the developing neocortex.	IGF1R CUX1	7.62e-04	20	71	2	26848828
Pubmed	A ubiquitin-based effector-to-inhibitor switch coordinates early brain, craniofacial, and skin development.	GLMN KLHL13 DNAH5	7.64e-04	87	71	3	37495603
Pubmed	A novel tandem affinity purification strategy for the efficient isolation and characterisation of native protein complexes.	CLASP1 KLC2 KLC1	7.64e-04	87	71	3	17979178
Interaction	CNPY3 interactions	VMP1 IGF1R CLASP1 SLITRK6 NRROS GAA PML ITPR2	1.31e-07	196	61	8	int:CNPY3
Interaction	CCNG1 interactions	CCDC125 ZZEF1 DDB1 NXF1	1.71e-05	51	61	4	int:CCNG1
Interaction	KLC4 interactions	KRT15 KRT16 KRT19 KLC2 KLC1	3.82e-05	125	61	5	int:KLC4
Interaction	TCHP interactions	CCDC125 KRT15 KRT16 KRT19 PCNT	4.78e-05	131	61	5	int:TCHP
Interaction	CDK18 interactions	CCDC125 KRT15 KRT16 PML COL1A1	4.78e-05	131	61	5	int:CDK18
Cytoband	14q32.33	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-30-3 IGHV3-74 IGHV3-66	1.57e-22	228	70	16	14q32.33
Cytoband	Ensembl 112 genes in cytogenetic band chr14q32	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 KLC1 IGHV3-74 IGHV3-66	1.64e-13	566	70	14	chr14q32
Cytoband	11q12-q13	DDB1 NXF1	3.42e-05	6	70	2	11q12-q13
Cytoband	17q21.2	KRT15 KRT16 KRT19	1.73e-04	70	70	3	17q21.2
Cytoband	17q23.1	VMP1 RNFT1	2.71e-04	16	70	2	17q23.1
Cytoband	Ensembl 112 genes in cytogenetic band chr17q23	VMP1 RNFT1 ACE	8.39e-04	120	70	3	chr17q23
Cytoband	Ensembl 112 genes in cytogenetic band chr11q12	CBLIF TCN1 DDB1 NXF1	1.95e-03	345	70	4	chr11q12
Cytoband	Ensembl 112 genes in cytogenetic band chr17q21	KRT15 KRT16 KRT19 COL1A1	5.97e-03	473	70	4	chr17q21
GeneFamily	Immunoglobulin heavy locus at 14q32.33	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-30-5 IGHV3-30-3 IGHV3-43D IGHV3-74 IGHV3-66	2.72e-22	187	48	17	349
GeneFamily	Keratins, type I	KRT15 KRT16 KRT19	5.49e-05	28	48	3	608
Coexpression	XU_CREBBP_TARGETS_DN	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	1.00e-22	56	67	13	MM642
Coexpression	YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	4.53e-19	102	67	13	MM872
Coexpression	RASHI_RESPONSE_TO_IONIZING_RADIATION_6	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	1.47e-17	132	67	13	MM996
Coexpression	YIH_RESPONSE_TO_ARSENITE_C5	KRT15 KRT19 PML	2.60e-06	11	67	3	M2023
Coexpression	SALVADOR_MARTIN_PEDIATRIC_TBD_ANTI_TNF_THERAPY_NONRESPONDER_POST_TREATMENT_DN	IGHV3-48 IGHV3-7 IGHV3-74	8.73e-06	16	67	3	M41742
Coexpression	SHEDDEN_LUNG_CANCER_GOOD_SURVIVAL_A12	CACNA1A IGHV3-33 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 ABCA12	1.69e-05	318	67	7	M2429
Coexpression	MATTIOLI_MGUS_VS_PCL	IGHV3-33 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7	1.87e-05	127	67	5	M10973
Coexpression	SMID_BREAST_CANCER_BASAL_UP	CACNA1A IGHV3-33 IGHV3-23 KRT15 KRT16 IGHV3-7 PEG3 JRKL PML	4.59e-05	662	67	9	M8124
CoexpressionAtlas	AravindRamakr_StemCell-hypoxiaGrown_fromBlastocyst-derived-humanEmbryonicStemCells_top-relative-expression-ranked_500_k-means-cluster#2	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-66	5.71e-11	163	64	10	Arv_SC-hpx_blastocyst_500_K2
CoexpressionAtlas	AravindRamakr_StemCell-H9hpx_top-relative-expression-ranked_500_k-means-cluster#3	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-66	1.15e-10	175	64	10	Arv_SC-H9hpx_500_K3
CoexpressionAtlas	AravindRamakr_StemCell-H9hpx_top-relative-expression-ranked_1000_k-means-cluster#4	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-66	2.94e-09	244	64	10	Arv_SC-H9hpx_1000_K4
CoexpressionAtlas	AravindRamakr_StemCell_from_inducedPluripotentialStemCells_derived from_from_fibroblast_top-relative-expression-ranked_1000_k-means-cluster#5	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-66	3.94e-09	183	64	9	Arv_SC_fibroblast_1000_K5
CoexpressionAtlas	AravindRamakr_StemCell-HD_top-relative-expression-ranked_1000_k-means-cluster#3	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-66	3.94e-09	183	64	9	Arv_SC-HD_1000_K3
CoexpressionAtlas	AravindRamakr_StemCell-hypoxiaGrown_fromBlastocyst-derived-humanEmbryonicStemCells_top-relative-expression-ranked_1000_k-means-cluster#2	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-66	6.72e-09	266	64	10	Arv_SC-hpx_blastocyst_1000_K2
CoexpressionAtlas	AravindRamakr_StemCell-H9hpx_top-relative-expression-ranked_500	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-66	2.01e-06	492	64	10	Arv_SC-H9hpx_500
CoexpressionAtlas	AravindRamakr_StemCell-hypoxiaGrown_fromBlastocyst-derived-humanEmbryonicStemCells_top-relative-expression-ranked_500	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-66	2.01e-06	492	64	10	Arv_SC-hpx_blastocyst_500
CoexpressionAtlas	AravindRamakr_StemCell-HD_top-relative-expression-ranked_500_k-means-cluster#2	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7	2.19e-06	126	64	6	Arv_SC-HD_500_K2
CoexpressionAtlas	AravindRamakr_StemCell_from_inducedPluripotentialStemCells_derived from_from_fibroblast_top-relative-expression-ranked_500_k-means-cluster#3	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7	3.87e-06	139	64	6	Arv_SC_fibroblast_500_K3
CoexpressionAtlas	AravindRamakr_StemCell-hypoxiaGrown_fromBlastocyst-derived-humanEmbryonicStemCells_top-relative-expression-ranked_2500_k-means-cluster#4	IGHV3-48 IGHV3-33 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-66	5.02e-06	426	64	9	Arv_SC-hpx_blastocyst_2500_K4
CoexpressionAtlas	ratio_induced-Ectoderm_vs_StemCell_top-relative-expression-ranked_2500_k-means-cluster#3	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-9 IGHV3-7 PEG3 RASL12 IGHV3-66	4.14e-05	848	64	11	ratio_ECTO_vs_SC_2500_K3
CoexpressionAtlas	PP_HSC_top-relative-expression-ranked_2500_k-means-cluster#3	IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 PEG3 RASL12	7.07e-05	339	64	7	PP_HSC_2500_K3
CoexpressionAtlas	BM Top 100 - urethra	KRT15 KRT19 SLITRK6 COL1A1	8.61e-05	77	64	4	BM Top 100 - urethra
CoexpressionAtlas	AravindRamakr_StemCell-H9hpx_top-relative-expression-ranked_2500_k-means-cluster#2	IGHV3-48 IGHV3-23 IGHV3-21 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-66	2.97e-04	428	64	7	Arv_SC-H9hpx_2500_K2
ToppCell	COVID_vent-Lymphocytic-Plasma_cell-IgM_Plasmablast\|COVID_vent / Disease condition, Lineage, Cell class and subclass	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-74 IGHV3-66	5.55e-20	196	68	14	026a06d8d2089806823e6f6453d3ede84ae93bc6
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	1.61e-18	185	68	13	08bc817908076734d66f2805cb954141f2cc5a18
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	1.61e-18	185	68	13	1704a12153a9b107bf03ecccd1a036cf61334d7a
ToppCell	5'-Adult-LargeIntestine-Hematopoietic-Plasma_cells\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	2.29e-18	190	68	13	79ee6d10dfbb775da149a1104da5823cf63bbb46
ToppCell	5'-Adult-LargeIntestine-Hematopoietic-Plasma_cells-IgA_plasma_cell\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	2.29e-18	190	68	13	18762ce78ed0b206ade19e1c8ff76a2647489f68
ToppCell	Tracheal-10x5prime-Immune_Lymphocytic-B-B_plasma\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	2.82e-18	193	68	13	282b47dae6043eabb1e13d41d91c07b5ec21cd65
ToppCell	Tracheal-10x5prime-Immune_Lymphocytic-B\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	3.70e-18	197	68	13	2662138671262b30508c5759038bcdcfe6551696
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	6.06e-17	178	68	12	107dae8b00c4257697a63700e72bb434cdb8406f
ToppCell	cellseq-Immune-Lymphocytic_B-Lymphocytic_B-Plasma\|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	8.50e-17	183	68	12	5ab4aa0304b832f98fff89b6c24ad5b7dd014c11
ToppCell	Mild_COVID-19-B_cell\|Mild_COVID-19 / Disease group,lineage and cell class （2021.01.30）	IGHV3-53 CACNA1A IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7 IGHV3-66	8.50e-17	183	68	12	dea119e2988e954475f557f0bbe12556a83e81a4
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgA\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	1.62e-16	193	68	12	34f6c13884fdf7f8a87f942fcb36a58cfac3f65d
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B-B_plasma\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	1.73e-16	194	68	12	6ef4aeb8d8e35e4df58ff2a8256caa2113291de9
ToppCell	Tracheal-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgG\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	1.73e-16	194	68	12	a4a70369541876e1192df8828b63e3d1746ae3d9
ToppCell	Biopsy_IPF-Immune-Plasma_cells\|Biopsy_IPF / Sample group, Lineage and Cell type	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	1.96e-16	196	68	12	a1b6a8000b86efcb07843998aa3a49bb1f54bcda
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgG\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	1.96e-16	196	68	12	fec21383435779bf4c632decd3d29c6ca7baebfb
ToppCell	COVID_non-vent-Lymphocytic-Plasma_cell\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	2.08e-16	197	68	12	1e63879633f20646e44873ae6b662f6faf4806fd
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-66	2.08e-16	197	68	12	9fe1b757f76c2d43d39aa9ac500eaba98723985c
ToppCell	367C-Lymphocytic-Plasma_cell-\|367C / Donor, Lineage, Cell class and subclass (all cells)	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7 IGHV3-66	1.69e-15	167	68	11	f2185eb72f0137136f6d71af2a70168fded6c940
ToppCell	367C-Lymphocytic-Plasma_cell\|367C / Donor, Lineage, Cell class and subclass (all cells)	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7 IGHV3-66	1.69e-15	167	68	11	5e768cf24699893e05d1bcb1c92dba2336943a64
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.0.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-66	4.13e-15	181	68	11	e47664a264a2c37390d1668ce04eef2e0172f4cb
ToppCell	3'-Broncho-tracheal-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-66	4.95e-15	184	68	11	15f2c10101ccc8ed059520fc082ee42593dff269
ToppCell	3'-Broncho-tracheal-Immune_Lymphocytic-Lymphocytic_B-plasma_cell\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-66	4.95e-15	184	68	11	a90a58d9e319afa1cd572e4c2f516fadc42f56e5
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Immune-Lymphocytic_B-Plasma_Cell-\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74	5.26e-15	185	68	11	0fff2608f507e019ebb69c27e58fd5be3b049bef
ToppCell	kidney_cells-Renal_AKI_(acute_kidney_injury)-Immune-Lymphocytic_B-Plasma_Cell\|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74	5.26e-15	185	68	11	79edc1eeb7b5b9123961ac3ecf398ee68d9dddb9
ToppCell	COVID_non-vent-Lymphocytic-Plasma_cell-IgM_Plasmablast\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-74	8.41e-15	193	68	11	7b4b0271e4fbece703876acb053ae236afb7cdba
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgA\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7 IGHV3-66	9.43e-15	195	68	11	13f4ee21568fd747608412d33559d10561dbb3c8
ToppCell	BAL-Mild-Lymphocyte-B\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CACNA1A IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7	1.03e-13	169	68	10	307571e57c3bfdf15f0fe1a8b36585e8e4f8a207
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.0.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74	1.30e-13	173	68	10	7e6bfe85f60834f317941b70d6e0dc3bd527d293
ToppCell	3'-Broncho-tracheal-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.0.1\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-66	1.94e-13	180	68	10	cea079bc02e08c46600eed05ab9924ec90e1e3d3
ToppCell	BAL-Mild-Lymphocyte-B-B_cell-B_cell\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	IGHV3-53 CACNA1A IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-7 IGHV3-66	2.42e-13	184	68	10	3f8a359e40bebe58545f708682e5e5d1b70cf5cb
ToppCell	BAL-Mild-Lymphocyte-B-B_cell-B_cell-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	IGHV3-53 CACNA1A IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-7 IGHV3-66	2.42e-13	184	68	10	64bede8db709fd32f40c03265b96f0b12155bb8a
ToppCell	BAL-Mild-Lymphocyte-B-B_cell\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-53 CACNA1A IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-7 IGHV3-66	2.56e-13	185	68	10	609080adb2cfb105bb7b8efb617553833299f371
ToppCell	Mild_COVID-19-B_cell-B_cell\|Mild_COVID-19 / Disease group,lineage and cell class （2021.01.30）	IGHV3-53 CACNA1A IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-7 IGHV3-66	2.70e-13	186	68	10	855a5a00ba2aa1b5c63b8db56d026ddecc546050
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.1.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	3.00e-13	188	68	10	6844cebca177fdf38b21a40d606230a033717a3a
ToppCell	5'-Adult-LargeIntestine-Hematopoietic\|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7 IGHV3-74	3.52e-13	191	68	10	d1d30279ed4612b4f62c225d9eabf0b8a7a09d11
ToppCell	COVID-19-Lymphoid-Plasma,_B_cells\|COVID-19 / Condition, Lineage and Cell class	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-20 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	3.91e-13	193	68	10	bffd97a73365e1dd23ff3b0320b4860f04ec091a
ToppCell	Biopsy_Other_PF-Immune-Plasma_cells\|Biopsy_Other_PF / Sample group, Lineage and Cell type	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-66	4.33e-13	195	68	10	d0305c6a68c9e361507b04db94f86873085d49b3
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgG\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	4.33e-13	195	68	10	f3f7f1a77a1edd2b50a8211c76fe289738eb04cf
ToppCell	Tracheal-10x5prime-Immune_Lymphocytic-B-B_plasma-B_plasma_IgA\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7	4.33e-13	195	68	10	df009b18898c10686f75cf72b4ec0eff18f5bb50
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_plasma\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7 IGHV3-66	4.56e-13	196	68	10	c38e7f533c619afe008de0e99042f7180c2da918
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7	4.80e-13	197	68	10	88b29d205237f07a9a26cc15a1cf4ed4816a4c4b
ToppCell	Parenchymal-10x5prime-Immune_Lymphocytic-B-B_cell\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-11	4.80e-13	197	68	10	76465bb2408c7c75f694e8f7cf1a606b796afc3a
ToppCell	Biopsy_Control_(H.)-Immune-Plasma_cells\|Biopsy_Control_(H.) / Sample group, Lineage and Cell type	IGHV3-53 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-66	4.80e-13	197	68	10	275f38ed7e477000e864cecf9b7d49ae134c3b6a
ToppCell	3'_v3-bone_marrow-Lymphocytic_B_plasma-Plasma_cells\|bone_marrow / Manually curated celltypes from each tissue	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-74 IGHV3-66	6.70e-12	175	68	9	51301f3f44d3e88397f367cedd1e2abaa2be4c6f
ToppCell	COPD-Lymphoid-B_Plasma\|World / Disease state, Lineage and Cell class	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7	6.70e-12	175	68	9	d73ee324479172501481b54967a0f3bd870fcf3a
ToppCell	metastatic_Brain-B_lymphocytes-MALT_B_cells\|metastatic_Brain / Location, Cell class and cell subclass	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-66	7.05e-12	176	68	9	50e207403d48ce1b55a78897adb5519a2430a626
ToppCell	Control-Lymphoid_P-Plasmablast\|Control / Disease group, lineage and cell class	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-74	7.05e-12	176	68	9	4b4416f342b732d2cc60133838728880326257d8
ToppCell	Control-Lymphoid_P\|Control / Disease group, lineage and cell class	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-74	7.05e-12	176	68	9	d895a6b295cd649273ff80ad7785a3e0ae4c728a
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Immune-Lymphocytic_B-Plasma_Cell\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74	7.42e-12	177	68	9	c2b0fb5921eea24d248d6e6ccb57c29b0832602c
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast-Plasmablast-\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-7 IGHV3-74	7.42e-12	177	68	9	4c434a7b7cc54cf4dac996bbc3f5124d9ef9a9cd
ToppCell	VE-plasma\|VE / Condition, Cell_class and T cell subcluster	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7	7.42e-12	177	68	9	0c1cc0834de55717cb4f69d020339060ce2c9a03
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast-Plasmablast\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-7 IGHV3-74	7.42e-12	177	68	9	d746122bf8d208c3aa4d156e8c12d0a0e555c6e5
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast\|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-7 IGHV3-74	7.42e-12	177	68	9	fc40918825b7e1eb6861df59dfca944778a64b98
ToppCell	kidney_cells-Hypertensive_with+without-CKD-Immune-Lymphocytic_B-Plasma_Cell-\|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group	IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74	7.42e-12	177	68	9	111fb0707ff37ca631d85bb5a09e067ffe568eb8
ToppCell	VE-plasma-\|VE / Condition, Cell_class and T cell subcluster	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7	7.42e-12	177	68	9	3a3c94cf30012e2aa266bc4d7fe772e45fa90f6d
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-7 IGHV3-74	8.21e-12	179	68	9	837ed81f18257f444eaeadc4fac89deedd4e3061
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast-Plasmablast-Plasmablast\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7	8.21e-12	179	68	9	494febe77c6d4e6a2c6f0928bbf4c84b0301f188
ToppCell	PBMC-Control-Lymphocyte-B-Plasmablast-Plasmablast\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-7 IGHV3-74	8.21e-12	179	68	9	b6ee4f41d8fb5f047b7bdd8489dda0a89fc6d43f
ToppCell	BAL-Severe-Lymphocyte-B-Plasmablast-Plasmablast-Plasmablast\|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-53 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-66	8.64e-12	180	68	9	6a777a308fa3160d31eda468db930e71862020b2
ToppCell	healthy_donor-Lymphocytic-Plasma_cell\|healthy_donor / Disease condition, Lineage, Cell class and subclass	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-7 IGHV3-74 IGHV3-66	1.28e-11	188	68	9	bd53b0371154cff680226897b61c9809a239d1b6
ToppCell	Parenchymal-10x3prime_v2-Immune_Lymphocytic-B-B_plasma-B_plasma_IgG\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-74 IGHV3-66	1.77e-11	195	68	9	2d18f08f33f3b261c77b8adf87d1a184cc6d7400
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_cell\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7	1.85e-11	196	68	9	e9fe5090452ffdde4bb81b62d57037d823281d00
ToppCell	Parenchymal-10x3prime_v2-Immune_Lymphocytic-B-B_plasma\|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-74 IGHV3-66	1.85e-11	196	68	9	b3d5540fe8ab9a9cbb9ab5350f5cb0e1aae93584
ToppCell	COVID_vent-Lymphocytic-Plasma_cell\|COVID_vent / Disease condition, Lineage, Cell class and subclass	IGHV3-53 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-9 IGHV3-7	2.03e-11	198	68	9	e84c5f712e1dea548d0e2aba6625598f9671d3a0
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_cell-B_naive\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7 IGHV3-74	2.03e-11	198	68	9	79c690d21d3420d0bb1a3b3b4ea2c9aa3810a219
ToppCell	Control-Control-Lymphocyte-B-Plasmablast\|Control / Disease, condition lineage and cell class	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-7 IGHV3-74	2.12e-11	199	68	9	c11aa8bca3723a886e7082ae48bb922dd8396be4
ToppCell	healthy_donor-Lymphocytic-Plasma_cell-IgG_Plasmablast\|healthy_donor / Disease condition, Lineage, Cell class and subclass	IGHV3-53 IGHV3-43 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-9 IGHV3-7 IGHV3-74	8.77e-11	152	68	8	a2ba2d95ac9010e1a62db34dcad10d004f8a90cc
ToppCell	BAL-Mild-Lymphocyte-B-B_cell-B_cell-B_activate-7\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CACNA1A IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-7	2.15e-10	170	68	8	ee2ee67d90ae4596de8ccd620e37c82cf51651d4
ToppCell	BAL-Mild-Lymphocyte-B-B_cell-B_cell\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CACNA1A IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-7	2.15e-10	170	68	8	d7ca0c6ce5d2b7de99346f87e07aa7fe728fa08a
ToppCell	BAL-Mild-Lymphocyte-B-B_cell\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	CACNA1A IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-7	2.15e-10	170	68	8	52787f6d529c285d9f0c04cc022710ead5b89b3f
ToppCell	3'-Broncho-tracheal-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.0.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-13 IGHV3-7	2.47e-10	173	68	8	0ca2169a275404118038c0489a48062879488765
ToppCell	(2)_Plasma_cells\|World / Lung cell shreds - cell class (v4) and cell subclass (v4)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-7 IGHV3-66	2.96e-10	177	68	8	ed3c936bb69f9bc7291b4f6cde1d204078117c48
ToppCell	-IPF_03\|World / lung cells shred on cell class, cell subclass, sample id	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-13 IGHV3-7	2.96e-10	177	68	8	ae2d2e138946535596fa30a55207f261cafda461
ToppCell	5'-Parenchyma_lung-Immune_Lymphocytic-Lymphocytic_B-plasma_cell-Plasma_cells-Plasma_cells_L.1.7.1.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	IGHV3-53 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-11 IGHV3-66	3.38e-10	180	68	8	e3877f6ef5f54ff689058b4c996ab1851822f871
ToppCell	Parenchymal-NucSeq-Immune_Lymphocytic-B-B_plasma-B_plasma_IgA\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20	5.88e-10	193	68	8	5c5543e7c83ecea44d23521246592c0301044173
ToppCell	Parenchymal-NucSeq-Immune_Lymphocytic-B-B_plasma\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-74	6.38e-10	195	68	8	0b0615553b9a1b60d666d074ce4260919e2d5642
ToppCell	Bronchial-10x5prime-Immune_Lymphocytic-B-B_cell-B_mature\|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-20 IGHV3-11 IGHV3-7	6.64e-10	196	68	8	c2e17f3b2217f20bd7f28a1db4aa7d9a95c52a9c
ToppCell	COVID_non-vent-Lymphocytic-Plasma_cell-IgG_Plasmablast\|COVID_non-vent / Disease condition, Lineage, Cell class and subclass	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-66	6.92e-10	197	68	8	b754fad4f3caae6de95df901fd96ea8697fe41b1
ToppCell	10x5'-blood-Lymphocytic_B_plasma\|blood / Manually curated celltypes from each tissue	IGHV3-48 IGHV3-33 IGHV3-20 IGHV3-13 IGHV3-11 IGHV3-7 IGHV3-74	3.25e-09	150	68	7	6bab0a8bf78ed7de9e1b67ede7496488f80f4863
ToppCell	368C-Lymphocytic-Plasma_cell-\|368C / Donor, Lineage, Cell class and subclass (all cells)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-21 IGHV3-11 IGHV3-74 IGHV3-66	5.55e-09	162	68	7	c21a54310b239d999bbc9d8fb5e8fda16e0bc336
ToppCell	368C-Lymphocytic-Plasma_cell\|368C / Donor, Lineage, Cell class and subclass (all cells)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-21 IGHV3-11 IGHV3-74 IGHV3-66	5.55e-09	162	68	7	f945688815229c8386cbcbf46deee7df316fa8d3
ToppCell	3'_v3-blood-Lymphocytic_B_plasma-Plasma_cells\|blood / Manually curated celltypes from each tissue	IGHV3-48 IGHV3-43 IGHV3-33 IGHV3-23 IGHV3-20 IGHV3-7 IGHV3-74	6.31e-09	165	68	7	1c0c24fe252b761cf879b83562e23c02f0b6489f
ToppCell	healthy_donor-Lymphocytic-Plasma_cell-IgM_Plasmablast\|healthy_donor / Disease condition, Lineage, Cell class and subclass	IGHV3-53 IGHV3-48 IGHV3-33 IGHV3-23 IGHV3-11 IGHV3-74 IGHV3-66	6.58e-09	166	68	7	2b7b580bec8d9467b0deaf97098065f72dbf2a4f
ToppCell	tumor_Lung-B_lymphocytes-Plasma_cells\|tumor_Lung / Location, Cell class and cell subclass	IGHV3-53 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-13 IGHV3-11 IGHV3-7	7.44e-09	169	68	7	b36b7632ce55fc7b6b8b66020563d360b3de6fd7
ToppCell	BAL-Mild-Lymphocyte-B\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	CACNA1A IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-7 IGHV3-66	1.20e-08	181	68	7	700adfb41e4e377530f0dd31be89e12f109f3469
ToppCell	10x_3'_v3-tissue-resident_(10x_3'_v3)-lymphocytic-B_lymphocytic-plasma_cell\|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-74	1.20e-08	181	68	7	f7b08f662eb77ee7a777c6525ddc3195046aaf65
ToppCell	Mild-Lymphoid-B\|Mild / Condition, Lineage, Cell class and cell subclass	CACNA1A IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-7 IGHV3-66	1.29e-08	183	68	7	9b64d2d143525e6f48a191facfd101462ff36324
ToppCell	Mild-Lymphoid-B-\|Mild / Condition, Lineage, Cell class and cell subclass	CACNA1A IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-7 IGHV3-66	1.29e-08	183	68	7	b5740f05a4dcdbbf24f7bf7a3f57ac01a5e75f60
ToppCell	367C-Lymphocytic-Plasma_cell-\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-20 IGHV3-11 IGHV3-7	1.34e-08	184	68	7	14a5288d861260f63fbe0cbea3569cf643e7597e
ToppCell	367C-Lymphocytic-Plasma_cell\|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)	IGHV3-48 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-20 IGHV3-11 IGHV3-7	1.34e-08	184	68	7	fc708a5c8a7b19fab973c72dc4383a7d30f8b59a
ToppCell	5'-GW_trimst-2-LymphNode-Hematopoietic-B_cells-Pre-B\|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	IGHV3-53 IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-13 IGHV3-7	1.39e-08	185	68	7	0fa7970709dc957dea95fabbd83263a0335babd5
ToppCell	PBMC-Mild-Lymphocyte-B-Plasmablast-Plasmablast\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7	1.61e-08	189	68	7	73ee4cfb1057832f700be59b6917dedde3e89880
ToppCell	PBMC-Mild-Lymphocyte-B-Plasmablast-Plasmablast-Plasmablast\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7	1.61e-08	189	68	7	a1bda6ed5c52a5d33d229018cb5982cae6305533
ToppCell	PBMC-Mild-Lymphocyte-B-Plasmablast-Plasmablast\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7	1.61e-08	189	68	7	31594cc59eb1c5b01407dfd72b1487ecca8bf5ec
ToppCell	PBMC-Mild-Lymphocyte-B-Plasmablast-Plasmablast-\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7	1.61e-08	189	68	7	c296660061b46e3abae1e7cf29df20274e5a8add
ToppCell	10x_3'_v3-bone_marrow_(10x_3'_v3)-lymphocytic-B_lymphocytic-plasma_cell\|bone_marrow_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type	IGHV3-53 IGHV3-48 IGHV3-43 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7	1.61e-08	189	68	7	5a42be62552d912d0abf68f00d75ac80bbd69f2c
ToppCell	3'_v3-bone_marrow-Lymphocytic_B_plasma\|bone_marrow / Manually curated celltypes from each tissue	IGHV3-53 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-7 IGHV3-74	1.61e-08	189	68	7	dceb011216deb4ffd830144a53c635c05dff5ec5
ToppCell	PBMC-Mild-Lymphocyte-B-Plasmablast\|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7	1.61e-08	189	68	7	f2daf4889ef98bbefe3e44832618ac102a75b4d9
ToppCell	PBMC-Mild-Lymphocyte-B-Plasmablast\|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09)	IGHV3-48 IGHV3-30 IGHV3-23 IGHV3-21 IGHV3-20 IGHV3-11 IGHV3-7	1.61e-08	189	68	7	9de17ade3cc3e9cd1394338bd048fb1ce64ac50f
ToppCell	COVID-19-Lymphoid-Plasma,_B_cells\|Lymphoid / Condition, Lineage and Cell class	IGHV3-43 IGHV3-33 IGHV3-30 IGHV3-23 IGHV3-20 IGHV3-11 IGHV3-7	1.73e-08	191	68	7	bcdadf83cb9653f9cc2a281e7c1095fe8f79173c
Computational	Genes in the cancer module 68.	KRT15 KRT16 KRT19	1.00e-04	26	38	3	MODULE_68
Computational	Keratin.	KRT15 KRT16 KRT19	1.00e-04	26	38	3	MODULE_298
Computational	Genes in the cancer module 153.	KRT15 KRT16 COL1A1	2.26e-04	34	38	3	MODULE_153
Computational	Genes upregulated in subsets of cells of a given type within various tumors	VMP1 KRT15 KRT19	7.12e-04	50	38	3	GAVISH_3CA_METAPROGRAM_EPITHELIAL_STRESS
Drug	homocysteine thiolactone	CBLIF KRT15 KRT16 KRT19 ACE COL1A1	6.66e-07	131	54	6	CID000107712
Drug	Atovaquone [95233-18-4]; Down 200; 11uM; PC3; HT_HG-U133A	CBLIF PCDH12 ACE LRRC23 PML COL1A1	6.71e-06	195	54	6	4201_DN
Drug	Tinidazole [19387-91-8]; Up 200; 16.2uM; MCF7; HT_HG-U133A	CBLIF KRT15 PEG3 AGBL2 PML ITPR2	6.90e-06	196	54	6	4370_UP
Drug	Norgestrel-(-)-D [797-63-7]; Up 200; 12.8uM; MCF7; HT_HG-U133A	CACNA1A CBLIF KRT15 ELK1 NEB COL1A1	7.11e-06	197	54	6	4730_UP
Drug	Ceftazidime pentahydrate [78439-06-2]; Up 200; 6.2uM; PC3; HT_HG-U133A	CACNA1A PCDH12 ZZEF1 LRRC23 PML ITPR2	7.11e-06	197	54	6	5054_UP
Drug	Acetaminophen [103-90-2]; Down 200; 26.4uM; MCF7; HT_HG-U133A	RNFT1 PPP1R37 KLC2 ELK1 LRRC23 PML	7.11e-06	197	54	6	3364_DN
Drug	Reserpine [50-55-5]; Down 200; 6.6uM; PC3; HT_HG-U133A	PEG3 PCDH12 ACE LRRC23 COL1A1 ITPR2	7.32e-06	198	54	6	4203_DN
Drug	AC1NUW81	CBLIF GLMN TCN1	1.88e-05	22	54	3	CID005462220
Drug	Velcade (bortezomib	GLMN IGF1R KRT15 KRT16 KRT19 CUX1 CHUK	2.78e-05	374	54	7	CID000093860
Drug	olomoucine II	KRT15 KRT16 KRT19	3.54e-05	27	54	3	CID005494414
Drug	Ciclopirox ethanolamine [41621-49-2]; Up 200; 15uM; HL60; HT_HG-U133A	CNNM2 ELK1 HMGCS1 NXF1 LRRC23	5.75e-05	174	54	5	2456_UP
Drug	1-2q	CACNA1A KRT15 KRT16 KRT19 BBS10 COL1A1	6.15e-05	289	54	6	CID000011820
Drug	hematoxilina	KRT16 KRT19 SPATA16 ACE COL1A1	7.30e-05	183	54	5	CID000010603
Drug	Sirius red	RASL12 ACE COL1A1	7.82e-05	35	54	3	CID005486818
Drug	Dequalinium dichloride [522-51-0]; Up 200; 7.6uM; MCF7; HT_HG-U133A	ABCA12 PPP1R37 HMGCS1 PML COL1A1	8.08e-05	187	54	5	5396_UP
Drug	ethyl-p-((E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-1-propenyl)benzoic acid	KRT16 KRT19	8.23e-05	6	54	2	ctd:C034814
Drug	Pregnenolone [145-13-1]; Down 200; 12.6uM; HL60; HT_HG-U133A	CACNA1A HMGCS1 NEB PML ITPR2	8.50e-05	189	54	5	2497_DN
Drug	Podophyllotoxin [518-28-5]; Up 200; 9.6uM; MCF7; HT_HG-U133A	CBLIF PPP1R37 ZZEF1 PML ITPR2	9.38e-05	193	54	5	6103_UP
Drug	Galanthamine hydrobromide [1953-04-4]; Down 200; 10.8uM; PC3; HT_HG-U133A	CBLIF SRD5A3 PCDH12 ACE COL1A1	9.38e-05	193	54	5	4186_DN
Drug	Simvastatin [79902-63-9]; Up 200; 9.6uM; MCF7; HT_HG-U133A	IGF1R DLC1 ZZEF1 PML COL1A1	9.61e-05	194	54	5	4828_UP
Drug	Methylhydantoin-5-(L) [40856-73-3]; Up 200; 35uM; MCF7; HT_HG-U133A	TCN1 HMGCS1 LRRC23 PML ITPR2	9.85e-05	195	54	5	3378_UP
Drug	Nabumetone [42924-53-8]; Down 200; 17.6uM; HL60; HT_HG-U133A	CACNA1A CNNM2 DLC1 HMGCS1 GAA	9.85e-05	195	54	5	3108_DN
Drug	Haloperidol [52-86-8]; Up 200; 10.6uM; MCF7; HT_HG-U133A	SRD5A3 HMGCS1 ZZEF1 PML COL1A1	9.85e-05	195	54	5	1539_UP
Drug	Adiphenine hydrochloride [50-42-0]; Up 200; 11.4uM; PC3; HT_HG-U133A	CNNM2 CLASP1 MED23 BBS10 ITPR2	9.85e-05	195	54	5	1831_UP
Drug	Tiletamine hydrochloride; Down 200; 15.4uM; HL60; HT_HG-U133A	CACNA1A CNNM2 GAA LRRC23 PML	9.85e-05	195	54	5	3137_DN
Drug	Bufexamac [2438-72-4]; Down 200; 18uM; HL60; HT_HG-U133A	RNFT1 ELK1 NEB ZZEF1 PML	1.01e-04	196	54	5	2382_DN
Drug	Prilocaine hydrochloride [1786-81-8]; Down 200; 15.6uM; MCF7; HT_HG-U133A	PPP1R37 AGBL2 LRRC23 PML COL1A1	1.01e-04	196	54	5	2314_DN
Drug	6-Furfurylaminopurine [525-79-1]; Down 200; 18.6uM; MCF7; HT_HG-U133A	KRT15 HMGCS1 LRRC23 PML ITPR2	1.01e-04	196	54	5	6813_DN
Drug	Thioproperazine dimesylate [2347-80-0]; Up 200; 6.2uM; MCF7; HT_HG-U133A	SRD5A3 PCDH12 NEB AGBL2 COL1A1	1.01e-04	196	54	5	2236_UP
Drug	benserazide hydrochloride; Down 200; 10uM; SKMEL5; HG-U133A	IGF1R KLC2 ZZEF1 PML COL1A1	1.01e-04	196	54	5	631_DN
Drug	Sulfathiazole [72-14-0]; Down 200; 15.6uM; PC3; HT_HG-U133A	CNNM2 PCDH12 ACE LRRC23 PML	1.03e-04	197	54	5	4183_DN
Drug	Erythromycin [114-07-8]; Up 200; 5.4uM; MCF7; HT_HG-U133A	DLC1 SRD5A3 PCDH12 PML COL1A1	1.03e-04	197	54	5	1510_UP
Drug	Asiaticoside [16830-15-2]; Up 200; 4.2uM; PC3; HT_HG-U133A	SRD5A3 RNFT1 MED23 PML ITPR2	1.03e-04	197	54	5	7244_UP
Drug	Dimethisoquin hydrochloride [2773-92-4]; Down 200; 13uM; PC3; HT_HG-U133A	KRT15 PCDH12 ACE PML COL1A1	1.03e-04	197	54	5	4207_DN
Drug	0393-0188; Up 200; 10uM; PC3; HT_HG-U133A	PEG3 RNFT1 BBS10 PML ITPR2	1.03e-04	197	54	5	7510_UP
Drug	Phenelzine sulfate [156-51-4]; Up 200; 17uM; HL60; HT_HG-U133A	CBLIF ELK1 ANO10 PCDH12 NEB	1.03e-04	197	54	5	2357_UP
Drug	N-Acetyl-DL-homocysteine Thiolactone [1195-16-0]; Up 200; 25.2uM; MCF7; HT_HG-U133A	TCN1 PCDH12 PML COL1A1 ITPR2	1.03e-04	197	54	5	3836_UP
Drug	Boldine [476-70-0]; Down 200; 12.2uM; HL60; HT_HG-U133A	CNNM2 TCN1 NEB PML COL1A1	1.03e-04	197	54	5	2148_DN
Drug	Indoprofen [31842-01-0]; Down 200; 14.2uM; HL60; HT_HG-U133A	CACNA1A DLC1 NEB PML ITPR2	1.03e-04	197	54	5	3007_DN
Drug	Furosemide [54-31-9]; Up 200; 12uM; MCF7; HT_HG-U133A	CACNA1A CBLIF KRT15 PCDH12 PML	1.06e-04	198	54	5	3197_UP
Drug	Nystatine [1400-61-9]; Down 200; 4.4uM; HL60; HT_HG-U133A	CNNM2 DLC1 NEB LRRC23 ITPR2	1.06e-04	198	54	5	2500_DN
Drug	Testosterone propionate [57-85-2]; Up 200; 11.6uM; MCF7; HT_HG-U133A	CBLIF DLC1 PCDH12 PML COL1A1	1.06e-04	198	54	5	2649_UP
Drug	Rolipram [61413-54-5]; Down 200; 14.6uM; PC3; HT_HG-U133A	CBLIF ZZEF1 ACE PML COL1A1	1.06e-04	198	54	5	6730_DN
Drug	Cinoxacin [28657-80-9]; Up 200; 15.2uM; MCF7; HT_HG-U133A	CNNM2 ELK1 PML COL1A1 ITPR2	1.06e-04	198	54	5	6257_UP
Drug	Vigabatrin [60643-86-9]; Down 200; 31uM; PC3; HT_HG-U133A	CNNM2 IGF1R ELK1 NEB PML	1.06e-04	198	54	5	6314_DN
Drug	Pentylenetetrazole [54-95-5]; Up 200; 29uM; MCF7; HT_HG-U133A	KRT15 RNFT1 PCDH12 ZZEF1 ITPR2	1.06e-04	198	54	5	2255_UP
Drug	Methimazole [60-56-0]; Down 200; 35uM; HL60; HT_HG-U133A	CNNM2 DLC1 PCDH12 CUX1 COL1A1	1.06e-04	198	54	5	2570_DN
Drug	16-phenyl tetranor Prostaglandin E2; Up 200; 10uM; MCF7; HT_HG-U133A	KRT15 SRD5A3 ABCA12 PML COL1A1	1.06e-04	198	54	5	7541_UP
Drug	Lisuride (S)(-) [18016-80-3]; Down 200; 11.8uM; MCF7; HT_HG-U133A	KLC2 ELK1 LRRC23 PML COL1A1	1.06e-04	198	54	5	5028_DN
Drug	Norgestrel-(-)-D [797-63-7]; Up 200; 12.8uM; MCF7; HT_HG-U133A	RPGRIP1 MYH8 DLC1 PPP1R37 COL1A1	1.08e-04	199	54	5	3606_UP
Drug	Nitrofural [59-87-0]; Down 200; 20.2uM; MCF7; HT_HG-U133A	CNNM2 ELK1 HMGCS1 NEB NXF1	1.08e-04	199	54	5	5321_DN
Drug	Iopamidol [60166-93-0]; Down 200; 5.2uM; HL60; HT_HG-U133A	TP53I3 PCDH12 PML COL1A1 ITPR2	1.08e-04	199	54	5	2732_DN
Drug	Epirizole [18694-40-1]; Down 200; 17uM; PC3; HT_HG-U133A	IGF1R TCN1 PEG3 RNFT1 KLC2	1.08e-04	199	54	5	7292_DN
Drug	iloprost; Down 200; 1uM; MCF7; HG-U133A	GLMN IGF1R PPP1R37 RASL12 ZZEF1	1.08e-04	199	54	5	488_DN
Drug	Sulfamerazine [127-79-7]; Up 200; 15.2uM; MCF7; HT_HG-U133A	CBLIF PPP1R37 PCDH12 NEB ITPR2	1.11e-04	200	54	5	4740_UP
Drug	Beta-sistosterol [83-46-5]; Up 200; 9.6uM; HL60; HT_HG-U133A	CNNM2 TP53I3 GAA PML COL1A1	1.11e-04	200	54	5	2912_UP
Drug	Clomipramine hydrochloride [17321-77-6]; Up 200; 11.4uM; MCF7; HT_HG-U133A	CBLIF DLC1 PPP1R37 PML COL1A1	1.11e-04	200	54	5	3182_UP
Drug	Noscapine [128-62-1]; Up 200; 9.6uM; MCF7; HT_HG-U133A	HMGCS1 PCDH12 NEB ZZEF1 LRRC23	1.11e-04	200	54	5	7204_UP
Drug	Etifenin [63245-28-3]; Up 200; 12.4uM; HL60; HT_HG-U133A	IGF1R PEG3 TP53I3 GAA ITPR2	1.11e-04	200	54	5	2477_UP
Drug	4-hydroxymercuribenzoate	CHUK COL1A1	1.97e-04	9	54	2	ctd:C030601
Drug	Apstatin	IGF1R RASL12 ACE	2.15e-04	49	54	3	CID000447280
Drug	Tranexamic Acid	KRT19 COL1A1	2.45e-04	10	54	2	ctd:D014148
Drug	adenosylcobalamin	CBLIF GLMN TCN1	2.72e-04	53	54	3	CID000424379
Drug	NSC34533	KRT15 KRT16 KRT19	2.87e-04	54	54	3	CID000003512
Drug	glycyl-L-leucine	ACE GAA COL1A1	2.87e-04	54	54	3	CID000092843
Drug	Acetazolamide	IGF1R PEG3 ITPR2	3.03e-04	55	54	3	ctd:D000086
Drug	Fe-C	KRT19 ABCA12 RASL12	3.20e-04	56	54	3	CID000447356
Drug	CK 6	KRT15 KRT16 KRT19	3.55e-04	58	54	3	CID000447960
Drug	AC1L1EKH	CBLIF TCN1	3.59e-04	12	54	2	CID000002831
Drug	nilvadipine	CACNA1A RASL12 ACE	3.92e-04	60	54	3	CID000004494
Drug	Ro 13-6298	KRT16 KRT19	4.24e-04	13	54	2	CID006437076
Drug	AC1N9ZZC	CACNA1A MYH8 ELK1 KLC1	4.32e-04	149	54	4	CID004369374
Drug	24-norursodeoxycholic acid	KRT19 COL1A1	4.93e-04	14	54	2	ctd:C081331
Drug	methylmalonic acid	CBLIF TCN1 PML	5.67e-04	68	54	3	CID000000487
Drug	NSC259969	RASL12 CHUK	5.68e-04	15	54	2	CID000429599
Drug	Divonex	KRT15 KRT16 KLC1	5.92e-04	69	54	3	CID000002522
Drug	DB04210	KRT19 DNAH5	6.49e-04	16	54	2	CID005287853
Drug	AC1L1B78	PEG3 ACE PML	6.70e-04	72	54	3	CID000001313
Drug	Monensin sodium salt [22373-78-0]; Up 200; 5.8uM; MCF7; HT_HG-U133A	CNNM2 KRT15 HMGCS1 NEB	6.79e-04	168	54	4	3443_UP
Drug	AC1Q6PMP	KRT16 ACE CUX1 COL1A1	6.94e-04	169	54	4	CID000103535
Drug	DDDs	RASL12 ACE	7.34e-04	17	54	2	CID000014360
Drug	gamma-CDs	RASL12 COL1A1	7.34e-04	17	54	2	CID000453205
Drug	2,3-xylidine	CBLIF TCN1	7.34e-04	17	54	2	CID000006893
Drug	T-E-A-T	IGF1R KRT16 COL1A1	7.84e-04	76	54	3	CID000086807
Drug	Strophantine octahydrate [11018-89-6]; Up 200; 5.4uM; MCF7; HT_HG-U133A	DLC1 ELK1 PML COL1A1	8.60e-04	179	54	4	2656_UP
Drug	Rescinnamin [24815-24-5]; Up 200; 6.4uM; MCF7; HT_HG-U133A	HMGCS1 LRRC23 PML COL1A1	8.96e-04	181	54	4	2785_UP
Drug	nocodazole	CBLIF RPGRIP1 GLMN MYH8 NXF1 PCNT	9.04e-04	477	54	6	CID000004122
Drug	AC1L9LFK	CBLIF KRT19	9.20e-04	19	54	2	CID000447957
Drug	5,6-dimethylbenzimidazole	CBLIF TCN1	9.20e-04	19	54	2	CID000000675
Drug	daunorubicin HCl; Up 200; 1uM; MCF7; HT_HG-U133A	TP53I3 NXF1 PML COL1A1	9.33e-04	183	54	4	7507_UP
Drug	Perphenazine [58-39-9]; Up 200; 10uM; MCF7; HT_HG-U133A	RNFT1 HMGCS1 PML COL1A1	9.52e-04	184	54	4	1540_UP
Drug	AC1O0UVD	CBLIF KRT19 COL1A1	9.78e-04	82	54	3	CID006102706
Drug	homocystine	CBLIF TCN1 COL1A1	9.78e-04	82	54	3	CID000010010
Drug	Gossypol [303-45-7]; Up 200; 7.8uM; HL60; HT_HG-U133A	SRD5A3 TCN1 NEB ITPR2	9.91e-04	186	54	4	2202_UP
Drug	17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A	TCN1 HMGCS1 ACE COL1A1	9.91e-04	186	54	4	5585_UP
Drug	fluphenazine dihydrochloride; Up 200; 10uM; MCF7; HT_HG-U133A	TCN1 HMGCS1 PML COL1A1	9.91e-04	186	54	4	5597_UP
Drug	Progesterone [57-83-0]; Down 200; 12.8uM; HL60; HT_HG-U133A	CNNM2 NEB GAA PML	9.91e-04	186	54	4	2426_DN
Drug	Ethacrynic acid [58-54-8]; Up 200; 13.2uM; HL60; HG-U133A	VMP1 CNNM2 ELK1 JRKL	1.01e-03	187	54	4	1565_UP
Drug	Sulfaphenazole [526-08-9]; Up 200; 12.8uM; PC3; HT_HG-U133A	CNNM2 PEG3 DDB1 PML	1.01e-03	187	54	4	1794_UP
Drug	Corticosterone [50-22-6]; Down 200; 11.6uM; MCF7; HT_HG-U133A	CNNM2 DLC1 RNFT1 PML	1.01e-03	187	54	4	3244_DN
Disease	tumor necrosis factor ligand superfamily member 11 measurement	IGHV3-21 IGHV3-11 IGHV3-7	2.49e-06	13	62	3	EFO_0010617
Disease	Left Ventricular Hypertrophy	ACE GAA COL1A1	1.97e-05	25	62	3	C0149721
Disease	Alzheimer's disease 1 (implicated_via_orthology)	KLC2 KLC1	9.06e-05	7	62	2	DOID:0080348 (implicated_via_orthology)
Disease	Cholangitis	KRT19 COL1A1	9.06e-05	7	62	2	C0008311
Disease	platelet component distribution width	VMP1 IGF1R DLC1 NUP210L AGBL2 ZZEF1 CUX1 GAA	1.77e-04	755	62	8	EFO_0007984
Disease	interventricular septum thickness	IGF1R ITPR2	1.93e-04	10	62	2	EFO_0009287
Disease	thyroid volume	IGF1R DNAH5	5.11e-04	16	62	2	EFO_0004865
Disease	Lung diseases	IGF1R ACE DNAH5	6.01e-04	78	62	3	C0024115
Disease	Lewy body dementia (is_marker_for)	IGF1R ELK1	7.26e-04	19	62	2	DOID:12217 (is_marker_for)
Disease	C-reactive protein measurement	VMP1 RPGRIP1 GLMN NUP210L SPATA16 PPP1R37 SLITRK6 ZZEF1 CUX1	8.91e-04	1206	62	9	EFO_0004458
Disease	Cardiac Arrhythmia	CNNM2 ACE	1.26e-03	25	62	2	C0003811
Disease	ergothioneine measurement	CACNA1A DNAH5	1.37e-03	26	62	2	EFO_0021163
Disease	primary biliary cholangitis (biomarker_via_orthology)	ACE COL1A1	1.59e-03	28	62	2	DOID:12236 (biomarker_via_orthology)
Disease	Ciliopathies	RPGRIP1 DNAH5 BBS10	1.62e-03	110	62	3	C4277690
Disease	Strabismus	RPGRIP1 DNAH5	1.70e-03	29	62	2	HP_0000486
Disease	IgA glomerulonephritis (is_implicated_in)	IGF1R ACE	1.82e-03	30	62	2	DOID:2986 (is_implicated_in)
Disease	osteoporosis (is_implicated_in)	IGF1R COL1A1	1.94e-03	31	62	2	DOID:11476 (is_implicated_in)

Protein segments in the cluster

Peptide	Gene	Start	Entry
MRKQNLLASREALYN	CACNA1A	781	O00555
NKTNMNYDKLSRALR	ELK1	51	P19419
KRQQYNALLSNMSRI	ACE	136	P12821
NSLLQRQLMQSFYSK	CUX1	481	P39880
LNSLNNFLLRVNMSK	ABCA12	1941	Q86UK0
MNYALLGNRKALAQL	CCDC180	311	Q9P1Z9
LRQLFKDLDLNYMTQ	BBS10	421	Q8TAM1
VQKSLARMLLNDFLN	HMGCS1	271	Q01581
LLGNKLDMAQYRQVT	RASL12	131	Q9NYN1
LRSRDNKYKQMLVNA	TP53I3	266	Q53FA7
KYRMDLVLQLKNNAS	ITPR2	2031	Q14571
RLKRTNGNTYMLLTN	PCDH12	401	Q9NPG4
NQNLYLVGASKIRML	ANO10	66	Q9NW15
DNSKNTLYLQMNSLR	IGHV3-66	91	A0A0C4DH42
KLTMQNLNDRLASYL	KRT19	81	P08727
RDNAKNSLYLQMNSL	IGHV3-11	91	P01762
RDNSKNSLYLQMNSL	IGHV3-43D	91	P0DP04
RDNSKNTLYLQMNSL	IGHV3-30-5	91	P0DP03
RDNAKNSLYLQMNSL	IGHV3-7	91	P01780
RDNSKNTLYLQMNSL	IGHV3-30-3	91	P0DP02
AMLSLLRYNANLTKM	CHUK	451	O15111
LRYNANLTKMKNTLI	CHUK	456	O15111
RDNAKNSLYLQMNSL	IGHV3-9	91	P01782
ENAKNSLYLQMNSLR	IGHV3-13	91	P01766
RDNAKNSLYLQMNSL	IGHV3-48	91	P01763
EMTNLKDIGLYNLRN	IGF1R	121	P08069
SREMKSLQYLNLRGN	LRRC23	241	Q53EV4
SALFRENLNKLMTNL	MYH8	651	P13535
NLSNNRLYRLDDMSS	NXF1	271	Q9UBU9
SLRNKSLQMNDYKIA	MED23	461	Q9ULK4
MQNLNDRLASYLDKV	KRT16	121	P08779
RDNAKNSLYLQMNSL	IGHV3-20	91	A0A0C4DH32
KITMQNLNDRLASYL	KRT15	106	P19012
IATMKRNYRAGLLQN	JRKL	331	Q9Y4A0
RDNAKNTLYLQMNSL	IGHV3-74	91	A0A0B4J1X5
RDNAKNSLYLQMNSL	IGHV3-21	91	A0A0B4J1V1
KQLQEKLNRLLYSMT	PCNT	2071	O95613
DNMENYRKLLSLVQL	PEG3	246	Q9GZU2
RDNSKNSLYLQMNSL	IGHV3-43	91	A0A0B4J1X8
TMLNILALVYRDQNK	KLC2	241	Q9H0B6
NMNLRELYLADNKLN	PPP1R37	246	O75864
RNAYITGKNLLMQAR	SRD5A3	186	Q9H8P0
AQKLLTYQLMSSDNN	CBLIF	71	P27352
FIYTAKLSLNMDNLQ	KLHL13	151	Q9P2N7
KMLKSDNAVLNQRYL	CCDC125	226	Q86Z20
MKPLLYSQLDANTRN	AGBL2	336	Q5U5Z8
RDNSKNTLYLQMNSL	IGHV3-23	91	P01764
RDNSKNTLYLQMNSL	IGHV3-30	91	P01768
AQQAMRKALTLRYAL	GAA	691	P10253
SWYNLLLDMQNRLNK	DDB1	1046	Q16531
LKERLNMFLQLYNES	DNAH5	2906	Q8TE73
TMLNILALVYRDQNK	KLC1	256	Q07866
YSKLRTLLLRDNNMG	NRROS	271	Q86YC3
NKYFRNMELKLQLAS	NUP210L	1016	Q5VU65
RDNSKNTLYLQMNSL	IGHV3-33	91	P01772
DNSKNTLYLQMNSLR	IGHV3-53	91	P01767
QNSDRIMASLNLLRY	GLMN	466	Q92990
KNRMEYLSLNILNGN	RPGRIP1	1016	Q96KN7
SFMNLTRLQKLYLNG	SLITRK6	406	Q9H5Y7
LKNLAQTYLARNMSE	PML	726	P29590
MEKLQYASLLSQLQR	SPATA16	456	Q9BXB7
AQMNLLQKYSLLKLT	DLC1	1026	Q96QB1
QTKLRELQLQYQASM	CCDC136	926	Q96JN2
MKLLNLYIKRAQTTN	CLASP1	1511	Q7Z460
KISRQQYQNALMASR	CNNM2	806	Q9H8M5
YMDQQTGNLKKALLL	COL1A1	1376	P02452
EKKYLRAMQANRSQL	RNFT1	31	Q5M7Z0
LKPLLNTMIQSNYNR	TCN1	36	P20061
NLAQRSLYKKVMLEN	ZNF470	41	Q6ECI4
LSMASVRQNLLLKYG	ZZEF1	511	O43149
SMAQSYAKRIQQRLN	VMP1	386	Q96GC9
LAKNNALNMNKRLYT	NEB	3196	P20929